Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

  |  Issue: May 2019  |  

Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.

References

  1. Khanna D, Spino C, Bush E, et al. Abatacept vs. placebo in early diffuse cutaneous systemic sclerosis—results of a phase 2 investigator initiated, double-blind, placebo-controlled, multicenter, randomized controlled trial study (abstract 900). Arthritis Rheumatol. 2018;70(suppl 10).
  2. Khanna D, Lin CJF, Kuwana M, et al. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: Results from a phase 3 randomized controlled trial (abstract 898). Arthritis Rheumatol. 2018;70(suppl 10).
  3. Distler O, Allanore Y, Denton CP, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis: A randomized, double-blind, placebo-controlled phase IIb study (RISE-SSc) (abstract 903). Arthritis Rheumatol. 2018;70(suppl 10).
  4. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. Lancet. 2016 Jun 25;387(10038):2630–2640.
  5. Kolstad KD, Li S, Steen V, et al. Long-term outcomes in systemic sclerosis-associated pulmonary arterial hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest. 2018 Oct;154(4):862–871.
  6. Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1).
  7. Sullivan K, Pinckney A, Goldmuntz E, et al. Myeloablative autologous hematopoietic stem cell transplantation for severe scleroderma: Long-term outcomes 6–11 years after entry on a randomized study comparing transplantation and cyclophosphamide (abstract 1820). Arthritis Rheumatol. 2018;70(suppl 10).

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Targeted Therapy for Scleroderma Fibrosis

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….